279 related articles for article (PubMed ID: 15378132)
1. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.
Antzelevitch C; Belardinelli L; Wu L; Fraser H; Zygmunt AC; Burashnikov A; Di Diego JM; Fish JM; Cordeiro JM; Goodrow RJ; Scornik F; Perez G
J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S65-83. PubMed ID: 15378132
[TBL] [Abstract][Full Text] [Related]
2. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.
Antzelevitch C; Belardinelli L; Zygmunt AC; Burashnikov A; Di Diego JM; Fish JM; Cordeiro JM; Thomas G
Circulation; 2004 Aug; 110(8):904-10. PubMed ID: 15302796
[TBL] [Abstract][Full Text] [Related]
3. Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine.
Sicouri S; Timothy KW; Zygmunt AC; Glass A; Goodrow RJ; Belardinelli L; Antzelevitch C
Heart Rhythm; 2007 May; 4(5):638-47. PubMed ID: 17467634
[TBL] [Abstract][Full Text] [Related]
4. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
Singh BN; Wadhani N
J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
[TBL] [Abstract][Full Text] [Related]
5. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome.
Wu L; Shryock JC; Song Y; Li Y; Antzelevitch C; Belardinelli L
J Pharmacol Exp Ther; 2004 Aug; 310(2):599-605. PubMed ID: 15031300
[TBL] [Abstract][Full Text] [Related]
6. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects.
Schram G; Zhang L; Derakhchan K; Ehrlich JR; Belardinelli L; Nattel S
Br J Pharmacol; 2004 Aug; 142(8):1300-8. PubMed ID: 15277312
[TBL] [Abstract][Full Text] [Related]
7. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
[TBL] [Abstract][Full Text] [Related]
8. Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model.
Antoons G; Oros A; Beekman JD; Engelen MA; Houtman MJ; Belardinelli L; Stengl M; Vos MA
J Am Coll Cardiol; 2010 Feb; 55(8):801-9. PubMed ID: 20170820
[TBL] [Abstract][Full Text] [Related]
9. Class I/B antiarrhythmic property of ranolazine, a novel antianginal agent, in dog and human cardiac preparations.
Szél T; Koncz I; Jost N; Baczkó I; Husti Z; Virág L; Bussek A; Wettwer E; Ravens U; Papp JG; Varró A
Eur J Pharmacol; 2011 Jul; 662(1-3):31-9. PubMed ID: 21550338
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
Eckardt L; Breithardt G; Haverkamp W
J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
[TBL] [Abstract][Full Text] [Related]
11. Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization.
Wu L; Ma J; Li H; Wang C; Grandi E; Zhang P; Luo A; Bers DM; Shryock JC; Belardinelli L
Circulation; 2011 Apr; 123(16):1713-20. PubMed ID: 21482963
[TBL] [Abstract][Full Text] [Related]
12. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits.
Wang WQ; Robertson C; Dhalla AK; Belardinelli L
J Pharmacol Exp Ther; 2008 Jun; 325(3):875-81. PubMed ID: 18322148
[TBL] [Abstract][Full Text] [Related]
13. Effects of ranolazine on torsades de pointes tachycardias in a healthy isolated rabbit heart model.
Sossalla S; Wallisch N; Toischer K; Sohns C; Vollmann D; Seegers J; Lüthje L; Maier LS; Zabel M
Cardiovasc Ther; 2014 Aug; 32(4):170-7. PubMed ID: 24785406
[TBL] [Abstract][Full Text] [Related]
14. Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome.
Shimizu W; Antzelevitch C
Circulation; 2000 Aug; 102(6):706-12. PubMed ID: 10931813
[TBL] [Abstract][Full Text] [Related]
15. Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2.
Parikh A; Mantravadi R; Kozhevnikov D; Roche MA; Ye Y; Owen LJ; Puglisi JL; Abramson JJ; Salama G
Heart Rhythm; 2012 Jun; 9(6):953-60. PubMed ID: 22245792
[TBL] [Abstract][Full Text] [Related]
16. Cellular basis for long QT, transmural dispersion of repolarization, and torsade de pointes in the long QT syndrome.
Shimizu W; Antzelevitch C
J Electrocardiol; 1999; 32 Suppl():177-84. PubMed ID: 10688323
[TBL] [Abstract][Full Text] [Related]
17. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.
Aiba T; Shimizu W; Inagaki M; Noda T; Miyoshi S; Ding WG; Zankov DP; Toyoda F; Matsuura H; Horie M; Sunagawa K
J Am Coll Cardiol; 2005 Jan; 45(2):300-7. PubMed ID: 15653031
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiologic basis for the antiarrhythmic actions of ranolazine.
Antzelevitch C; Burashnikov A; Sicouri S; Belardinelli L
Heart Rhythm; 2011 Aug; 8(8):1281-90. PubMed ID: 21421082
[TBL] [Abstract][Full Text] [Related]
19. Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart.
Wu L; Rajamani S; Li H; January CT; Shryock JC; Belardinelli L
Am J Physiol Heart Circ Physiol; 2009 Sep; 297(3):H1048-57. PubMed ID: 19592609
[TBL] [Abstract][Full Text] [Related]
20. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes.
Song Y; Shryock JC; Wu L; Belardinelli L
J Cardiovasc Pharmacol; 2004 Aug; 44(2):192-9. PubMed ID: 15243300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
